Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ABBV AbbVie
145.020-0.180-0.12%
Close
02/06 16:00 ET
145.0200.0000.00%
Pre Mkt Price 02/07 04:00 ET
High
146.330
Open
145.740
Turnover
625.34M
Low
144.805
Pre Close
145.200
Volume
4.30M
Pre-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
AbbVie Said to Push Two New Immune Medicines, Lift $2 Billion Cap on Dealmaking
AbbVie (ABBV) is focusing on its other immune drugs, Skyrizi and Rinvoq, to boost sales with its top-seller Humira expected to face declining sales amid tougher competition from lower-priced rivals, The Wall Street Journal reported Monday, citing an interview with Chief Executive Officer Richard Gonzalez.
Earnings Tracker: Disney, PayPal, AbbVie and Others Due This Week
Here's a rundown of this week's key results, as fourth-quarter earnings season continues. -- BP's record annual profit ( took the combined haul so far reported by Western oil majors
AbbVie Inc. Stock Falls Monday, Still Outperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) slid 0.12% to $145.02 Monday, on what proved to be an all-around poor tr
California Public Employees Retirement System Boosts Stock Holdings in AbbVie Inc. (NYSE:ABBV)
California Public Employees Retirement System boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 11.1% in the 3rd quarter, according to its most recent disclosure with the SEC. T
Abbvie Looks To Other Drugs As Humira Hit With Competition -- Market Talk
11:26 ET - AbbVie is turning to a pair of next-generation successors to replenish the billions of dollars in sales that will be lost as Humira becomes the target of rivals selling biosimilars at a sha
Spherix Global Insights Announces Special Coverage of Amgen's Amjevita Launch, Tracking Uptake and Perceptions of the First Commercially-available Biosimilar to AbbVie's Humira
According to a survey of autoimmune specialists, in the first week of launch, aided awareness of Amjevita is high, but willingness to prescribe is lacking. EXTON, Pa., Feb. 6, 2023 /PRNewswire/ -- AbbVie's Humira
Correction to AbbVie New Drugs Article -- WSJ
AbbVie's purchase of Allergan in 2020 delivered two migraine treatments named Qulipta and Ubrelvy. "AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira," at 5:30 a.m. ET, incorrectly
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
BMO Capital Adjusts Price Target on AbbVie to $167 From $169, Maintains Outperform Rating
10:14 AM EST, 02/06/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
AbbVie Price Target Cut to $167.00/Share From $169.00 by BMO Capital
AbbVie Price Target Cut to $167.00/Share From $169.00 by BMO Capital
Company Overview
More
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
CEO： Mr. Richard A. Gonzalez
Market： NYSE
Listing Date： 12/10/2012
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet